Bicycle Therapeutics Just Parked Its Best Bike in the Garage

Bicycle had been running a Phase 2 trial called Duravelo-2, hoping to use it as a springboard for accelerated approval. Accelerated approval is the FDA's fast lane: if your drug shows strong early signals in a serious disease, the agency can approve it based on Phase 2 data while you finish larger trials.

But after reviewing the trial design, the FDA delivered a gut punch. Regulators determined that the Duravelo-2 trial, even after dose selection was completed, was no longer acceptable as an approval path. The single-arm design (no comparison group) wasn't going to cut it. The FDA wanted a randomized Phase 2, which means more patients, more time, and a lot more money.

For a company burning through $319.65 million in operating expenses last year while posting a $218.96 million net loss, that's not just a setback. It's a forcing function.

The Math Behind the Machete

Bicycle ended 2025 with $628 million in cash. That sounds like a lot, but at the rate they were spending, the runway only stretched into late 2027. The restructuring changes that math dramatically.

By cutting half of its annual operating costs and reducing headcount from 288 to roughly 200, Bicycle expects to extend its cash runway into 2030. The layoffs will result in one-time restructuring costs, a relatively small price for three extra years of survival.

There's also a bright spot in the financials that's easy to miss. Collaboration revenue nearly doubled in 2025, hitting $72.59 million compared to $35.28 million the year before. Partners are still interested in the platform, even if Bicycle's own lead program hit a wall.

So What's Left in the Garage?

Bicycle isn't shutting down. It's pivoting, and the new direction is radioactive (literally).

The company is redirecting resources toward Bicycle Radio Conjugates (BRCs), which swap the chemical toxin payload for a radioactive isotope. Radiopharmaceuticals are one of the hottest areas in oncology right now, and Bicycle's small peptide platform could be a natural fit: the rapid tumor penetration that makes BTCs interesting for toxin delivery could be even more valuable for delivering radiation directly to tumors.

The pipeline now centers on a few key programs:

• BT5528, which targets a protein called EphA2. Phase 1 combination data with Bristol Myers Squibb's Opdivo is expected in the first half of 2026.
• BT1702, a radio conjugate targeting MT1-MMP, with the first company-sponsored clinical trial expected in 2027.
• A handful of preclinical radioconjugate programs using isotopes like lead-212.

Zelenectide pevedotin isn't dead, exactly. Bicycle is converting Duravelo-2 into the randomized Phase 2 the FDA wants. But internal investment is being deprioritized, which in biotech-speak usually means "we'll get back to this if we can afford to."

The company also appointed Jennifer Perry as its new COO, effective March 17, signaling that the restructuring comes with fresh operational leadership.

The Bigger Picture

Bicycle's retreat raises uncomfortable questions about the next-generation ADC space. The whole thesis behind BTCs, peptide-drug conjugates, and similar platforms is that smaller, nimbler delivery vehicles could outperform the bulky antibodies that dominate the market. But when your best clinical asset gets stalled by regulatory hurdles, investors start wondering whether "better in theory" translates to "better in practice."

The timing is notable, too. Oncology biotech funding has actually been fairly robust; venture rounds are getting larger, and the FDA approved more oncology drugs than any other category in 2025. Radiopharmaceuticals in particular are attracting serious capital. Bicycle's pivot toward radioconjugates is a bet that it can ride that wave.

But pivots are risky. The company went from having a lead program with compelling Phase 2 data to essentially starting over with earlier-stage assets. The cash runway extension into 2030 buys time, but time without a clear path to revenue is just a slower clock.

For Bicycle's remaining 200 employees, the next 12 months will tell the story. BT5528 data and early radioconjugate results could validate the pivot. Or they could confirm that the bicycle, however elegantly engineered, still needs a road to ride on.